Table 2.
PSG and demographic measures.
| Non medicated controls | Medicated controls | RBD patients | F(2,24) value | ANOVA p value | |
|---|---|---|---|---|---|
| Age | 46.8 ± 12.5 | 47.4 ± 11 | 49.7 ± 11 | 0.155 | 0.858 |
| Sex (F/M) | 3/6 | 3/6 | 3/6 | N/A | |
| TST (min) | 365.7 ± 70.8 | 396.6 ± 75.7 | 359.6 ± 74.7 | 0.649 | 0.532 |
| WASO (min) | 75.0 ± 47.1 | 89.8 ± 36.2 | 128.4 ± 58.5 | 2.957 | 0.071 |
| SOL (min) | 18.2 ± 35.6 | 37.9 ± 32.3 | 26.2 ± 25.2 | 0.902 | 0.419 |
| REML (min) | 91.4 ± 30.1 | 174.8 ± 91.7 | 183.1 ± 108.0 | 3.311 | 0.053 |
| SE (%) | 80.0 ± 15.0 | 75.9 ± 9.9 | 70.4 ± 13.0 | 1.215 | 0.314 |
| N1 (%) | 4.5 ± 2.3*^ | 12.8 ± 8.4^ | 8.2 ± 4.4 * | 4.874 | 0.017 |
| N2 (%) | 58.2 ± 9.5 | 63.4 ± 12.9 | 64.0 ± 12.3 | 0.686 | 0.513 |
| N3 (%) | 14.9 ± 8.9^ | 4.8 ± 4.4^ | 8.6 ± 9.7 | 3.609 | 0.043 |
| REM (%) | 22.4 ± 3.8 | 19.1 ± 9.4 | 19.2 ± 8.1 | 0.588 | 0.563 |
| Tonic REM (%) | 84.0 ± 7.2 | 76.3 ± 11.8 | 73.1 ± 11.8 | 1.934 | 0.10 |
| Phasic REM (%) | 16.0 ± 7.2 | 23.7 ± 11.8 | 26.9 ± 11.8 | 1.934 | 0.10 |
| ArI(#/h) | 12.7 ± 4.6 | 15.5 ± 7.9 | 15.8 ± 4.2 | 0.778 | 0.471 |
| AHI (#/h) | 5.8 ± 5.85 | 8.2 ± 6.3 | 6.1 ± 6.7 | 0.364 | 0.699 |
| PLMI (#/h) | 1.3 ± 0.59 | 1.06 ± 1.0 | 0.6 ± 1.0 | 1.427 | 0.260 |
Mean values (± standard deviation). Percentage values for sleep stages are expressed per total sleep time (TST).
AHI apnea–hypopnea index, ArI Arousal index, PLMI Periodic leg movement index, SE Sleep efficiency (TST per time in bed), REML Rapid eye movement onset latency, SOL Sleep onset latency, WASO Wake after sleep onset.
^ and *indicate significant unpaired t-test at α < 0.05 between non-medicated and medicated controls, and between non-medicated controls and RBD patients respectively. Significant p values for the main ANOVA test are indicated in bold.